title: Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
abstract: We compared therapeutic lipid target achievements among patients with diabetes or coronary heart disease (CHD) in Oman. A retrospective chart review of 94 patients was conducted at an outpatient clinic in Sultan Qaboos University Hospital, Muscat, Oman. The variables included low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apo B). The overall mean age of the cohort was 59 ± 12 years, 54% were male, 66% were diabetic, 48% hypertensive, 45% had CHD, 94% were on simvastatin, 4% were on fenofibrate, and 2% were on both simvastatin and fenofibrate. Lipid goal attainments of calculated LDL-C (<2.6 mmol/L), apo B (<0.9 g/L), and non-HDL-C (<3.36 mmol/L) were reached in 52%, 39%, and 53% of the patients, respectively. A significant proportion of high-risk patients treated with lipid-lowering agents reach LDL-C but not the apo B treatment targets, suggesting that the use of apo B target values should also be considered.
authors.affiliation: 1Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman.
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Waili
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Al-Zakwani
authors.forename: Tamima
authors.initials: T
authors.lastname: Al-Dughaishi
authors.forename: Yajnavalka
authors.initials: Y
authors.lastname: Baneerje
authors.forename: Hilal
authors.initials: H
authors.lastname: Al-Sabti
authors.forename: Khamis
authors.initials: K
authors.lastname: Al-Hashmi
authors.forename: Hatem
authors.initials: H
authors.lastname: Farhan
authors.forename: Khadija Al
authors.initials: KA
authors.lastname: Habsi
authors.forename: Ali T
authors.initials: AT
authors.lastname: Al-Hinai
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Rasadi
mesh_terms: D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000453:epidemiology; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009850:Oman / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D019821:Simvastatin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001053:Apolipoproteins; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids; D019821:Simvastatin; D011345:Fenofibrate
keywords: Oman; apolipoprotein B; coronary heart disease; diabetes mellitus; low-density lipoprotein cholesterol